Discovery of SCH 900188: A potent hepatitis C virus NS5B polymerase inhibitor prodrug as a development candidate

ACS Medicinal Chemistry Letters

Volumn 5, Issue 3, 2014, Pages 244-248

  Chen, Kevin X ^a   Venkatraman, Srikanth ^a   Anilkumar, Gopinadhan N ^a   Zeng, Qingbei ^a   Lesburg, Charles A ^a   Vibulbhan, Bancha ^a   Velazquez, Francisco ^a   Chan, Tin Yau ^a   Bennet, Frank ^a   Jiang, Yueheng ^a   Pinto, Patrick ^a   Huang, Yuhua ^a   Selyutin, Oleg ^a   Agrawal, Sony ^a   Huang, Hsueh Cheng ^a   Li, Cheng ^a   Cheng, Kuo Chi ^a   Shih, Neng Yang ^a   Kozlowski, Joseph A ^a   Rosenblum, Stuart B ^a   Njoroge, F George ^a   more..

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

HCV; hepatitis C virus; NS5B polymerase; polymerase inhibitor; prodrug

Indexed keywords

ANTIVIRUS AGENT; INDOLE; NITROGEN; NONSTRUCTURAL PROTEIN 5B; PRODRUG; QUINAZOLINONE DERIVATIVE; RNA DIRECTED RNA POLYMERASE INHIBITOR; SCH 900188; UNCLASSIFIED DRUG;

AMES TEST; ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; DOG; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG STRUCTURE; HAPLORHINI; HEPATITIS C VIRUS; IN VITRO STUDY; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; RAT;

EID: 84894682467     PISSN: None     EISSN: 19485875     Source Type: Journal    
DOI: 10.1021/ml400192w     Document Type: Article

References (19)

1. Cohen, J. The scientific challenge of hepatitis C Science 1999, 285, 26-30
2. Shepard, C. W.; Finelli, L.; Alter, M. J. Global epidemiology of hepatitis C virus infection Lancet Infect. Dis. 2005, 5, 558-567
3. Sheridan, C. New Merck and Vertex drugs raise standard of care in hepatitis C Nat. Biotechnol. 2011, 29, 553-554
4. Choo, Q. L.; Kuo, G.; Weiner, A. J.; Weiner, A. J.; Overby, L. R.; Bradley, D. W.; Houghton, M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome Science 1989, 244, 359-362
5. Chen, K. X.; Njoroge, F. G. A review of HCV protease inhibitors Curr. Opin. Invest. Drugs 2009, 10, 821-837
6. Watkins, W. J.; Ray, A. S.; Chong, L. S. HCV NS5B polymerase inhibitors Curr. Opin. Drug Discovery Dev. 2010, 13, 441-465
7. Njoroge, F. G.; Chen, K. X.; Shih, N.-Y.; Piwinski, J. J. Challenges in modern drug discovery: A case study of boceprevir, an HCV protease inhibitor for the treatment of hepatitis C virus infection Acc. Chem. Res. 2008, 41, 50-59
8. Perni, R. B.; Almquist, S. J.; Byrn, R. A.; Chandorkar, G.; Chaturvedi, P. R.; Courtney, L. F.; Decker, C. J.; Dinehart, K.; Gates, C. A.; Harbeson, S. L.; Heiser, A.; Kalkeri, G.; Kolaczkowski, E.; Lin, K.; Luong, Y.-P.; Rao, B. G.; Taylor, W. P.; Thomson, J. A.; Tung, R. D.; Wei, Y.; Kwong, A. D.; Lin, C. Preclinical profile of VX-950, a potent, selective, and orally, bioavailable inhibitor of hepatitis C virus NS3-4A serine protease Antimicrob. Agents Chemother. 2006, 50, 899-909
9. Behrens, S. E.; Tomei, L.; De Francesco, R. Identification and properties of the RNA-dependent RNA polymerase of hepatitis C virus EMBO J. 1996, 15, 12-22
10. Quinkert, D.; Bartenschlager, R.; Lohmann, V. Quantitative analysis of the hepatitis C virus replication complex J. Virol. 2005, 79, 13594-13605
11. Lesburg, C. A.; Cable, M. B.; Ferrari, E.; Hong, Z.; Mannarino, A. F.; Weber, P. C. Crystal structure of the RNA-dependent RNA polymerase from hepatitis C virus reveals a fully encircled active site Nat. Struct. Biol. 1999, 6, 937-943
12. Liu, Y.; He, Y.; Molla, A. Hepatitis C Virus Polymerase as a Target for Antiviral Drug Intervention: Non-Nucleoside Inhibitors. In Antiviral Research: Strategies in Antiviral Drug Discovery; LaFemina, R. L., Ed.; ASM Press: Washington, DC., 2009; pp 137-151.
13. Watkins, W. J.; Ray, A. S.; Chong, L. S. HCV NS5B polymerase inhibitors Curr. Opin. Drug Discovery Dev. 2010, 13, 441-465
14. Kneteman, N. M.; Howe, A. Y.; Gao, T.; Lewis, J.; Pevear, D.; Lund, G.; Douglas, D.; Mercer, D. F.; Tyrrell, D. L.; Immermann, F.; Chaudhary, I.; Speth, J.; Villano, S. A.; O'Connell, J.; Collett, M. HCV796: A selective nonstructural protein 5B polymerase inhibitor with potent anti-hepatitis C virus activity in vitro, in mice with chimeric human livers, and in humans infected with hepatitis C virus Hepatology 2009, 49, 745-52
15. Chen, K. X.; Vibulbhan, B.; Yang, W.; Sannigrahi, M.; Velazquez, F.; Chan, T. Y.; Venkatraman, S.; Anilkumar, G. N.; Zeng, Q.; Bennet, F.; Jiang, Y.; Lesburg, C. A.; Duca, J.; Pinto, P.; Gavalas, S.; Huang, Y.; Wu, W.; Selyutin, O.; Agrawal, S.; Feld, B.; Huang, H. C.; Li, C.; Cheng, K. C.; Shih, N. Y.; Kozlowski, J. A.; Rosenblum, S. B.; Njoroge, F. G. Structure-activity- relationship (SAR) development and discovery of potent indole-based inhibitors of the hepatitis C virus (HCV) NS5B polymerase J. Med. Chem. 2012, 55, 754-765
16. Ferrari, E.; He, Z.; Palermo, R. E.; Huang, H. C. Hepatitis C virus NS5B polymerase exhibits distinct nucleotide requirements for initiation and elongation J. Biol. Chem. 2008, 283, 33893-33901
17. Lohmann, V.; Körner, F.; Koch, J.-O.; Herian, U.; Theilmann, L.; Bartenschlager, R. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line Science 1999, 285, 110-113
18. Ishiyama, T.; Murata, M.; Miyaura, N. Palladium(0)-catalyzed cross-coupling reaction of alkoxydiboron with haloarenes: A direct procedure for arylboronic esters J. Org. Chem. 1995, 60, 7508-7510
19. Rautio, J.; Kumpulainen, H.; Heimbach, T.; Oliyai, R.; Oh, D.; Järvinen, T.; Savolainen, J. Prodrugs: design and clinical applications Nature Rev. Drug Discovery 2008, 7, 225-270